CPO301

Antibody–drug conjugate

Also known as SYS6010

Phase 3topline reported

Evidence outlook

Non-Small Cell Lung Cancer: topline reported 2026-08-26

The sponsor reported topline results on 2026-08-26 (Phase 3 SYNSTAR01 (NCT06927986) of SYS6010 met its pre-specified PFS primary endpoint at interim analysis). The announcement is listed under Regulatory events.

Latest reported trial: NCT06927986 · Phase 3 · met primary endpoint · grade pending

Also in development:Head and Neck Squamous Cell Carcinoma · Phase 3Breast Cancer · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (10)
Breast Cancer
NCT07406542 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-04-01 – 2030-04-01 · Recurrent or Metastatic Breast Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT07758621 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-08-15 – 2028-12-01 · Head and Neck Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07633873 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-06-02 – 2029-05-30 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07925021 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-11-06 – 2030-12-01 · Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
NCT07417735 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-03-18 – 2029-12-31 · Locally Advanced/Metastatic/Recurrent ESCC
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT07251062 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-12-30 – 2030-12-30 · Esophageal Squamous Cell Carcinoma
What this study did
Phase 2 (2)
Head and Neck Squamous Cell Carcinoma
NCT07254585 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-12-12 – 2028-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07256509 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-11-30 – 2032-06-30 · Non-Small Cell Lung Cancer
What this study did
Phase 1/2 (3)
Breast Cancer
NCT06775236 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-03-20 – 2028-01-15 · Advanced Solid Tumors, Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07472647 · Shanghai JMT-Bio Inc.
2026-02-28 – 2030-02-28 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07241936 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-11-13 – 2028-10-30 · Advanced Solid Tumors
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT07692048 · Sichuan University
2026-06-30 – 2028-12-31 · NSCLC
What this study did
Other / comorbidity
NCT05948865 · Conjupro Biotherapeutics, Inc.
2023-06-06 – 2027-08 · Cancer, Cancer, Lung
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07104877 · Fujian Cancer Hospital
2024-04-18 – 2026-04-30 · Colorectal Cancer, Gastric Cancer (GC), Gastrointestinal Tumors
What this study did

Competitive landscape

This mechanism is crowded: 41 other tracked programmes target it, 6 of them ahead of this one.

This drug's own stage for Head and Neck Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CPO301: this drugPhase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
CetuximabApprovedMonoclonal antibodyEGFRPartial signal
NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048).
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
NBTXR3Phase 3NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OrdastobartPhase 2/3Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
PepinemabPhase 1/2Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow CPO301 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-11-30 · NCT07256509 · CT.gov ↗
What to watch
December 2026 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-12 · NCT07376382 · CT.gov ↗
What to watch
2027 (6)
May 2027 (1)
Phase 1Cancer, Cancer, LungRecruiting
Est. primary completion 2027-05 · NCT05948865 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2027-06-15 · NCT06775236 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07633873 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-10-30 · NCT07241936 · CT.gov ↗
What to watch
December 2027 (2)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07442565 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07692048 · CT.gov ↗
What to watch
2028 (3)
June 2028 (1)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07254585 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-09-15 · NCT07758621 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Locally Advanced/Metastatic/Recurrent ESCCNot yet recruiting
Est. primary completion 2028-12-31 · NCT07417735 · CT.gov ↗
What to watch
2029 (6)
February 2029 (1)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-02-28 · NCT07472647 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2029-04-01 · NCT07406542 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT07672223 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2029-10-01 · NCT07925021 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07251062 · CT.gov ↗
What to watch
Phase 3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07924111 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 August 2026Topline resultPhase 3 SYNSTAR01 (NCT06927986) of SYS6010 met its pre-specified PFS primary endpoint at interim analysis